DK1604016T3 - In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler - Google Patents

In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler

Info

Publication number
DK1604016T3
DK1604016T3 DK04715780T DK04715780T DK1604016T3 DK 1604016 T3 DK1604016 T3 DK 1604016T3 DK 04715780 T DK04715780 T DK 04715780T DK 04715780 T DK04715780 T DK 04715780T DK 1604016 T3 DK1604016 T3 DK 1604016T3
Authority
DK
Denmark
Prior art keywords
cells
monocytes
dendritic
csf
dendritic cells
Prior art date
Application number
DK04715780T
Other languages
Danish (da)
English (en)
Inventor
Benjamin A Tjoa
Marnix L Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Application granted granted Critical
Publication of DK1604016T3 publication Critical patent/DK1604016T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK04715780T 2003-02-27 2004-02-27 In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler DK1604016T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45101503P 2003-02-27 2003-02-27
PCT/US2004/006119 WO2004076651A2 (en) 2003-02-27 2004-02-27 Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines

Publications (1)

Publication Number Publication Date
DK1604016T3 true DK1604016T3 (da) 2009-05-18

Family

ID=32927693

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04715780T DK1604016T3 (da) 2003-02-27 2004-02-27 In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler

Country Status (20)

Country Link
US (4) US8389278B2 (cg-RX-API-DMAC7.html)
EP (1) EP1604016B1 (cg-RX-API-DMAC7.html)
JP (1) JP4762887B2 (cg-RX-API-DMAC7.html)
KR (2) KR20110106474A (cg-RX-API-DMAC7.html)
CN (1) CN1784488B (cg-RX-API-DMAC7.html)
AT (1) ATE420946T1 (cg-RX-API-DMAC7.html)
AU (2) AU2004214896A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407900A (cg-RX-API-DMAC7.html)
CA (1) CA2517295C (cg-RX-API-DMAC7.html)
CY (1) CY1109099T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004019057D1 (cg-RX-API-DMAC7.html)
DK (1) DK1604016T3 (cg-RX-API-DMAC7.html)
ES (1) ES2321939T3 (cg-RX-API-DMAC7.html)
IL (1) IL170512A (cg-RX-API-DMAC7.html)
MX (1) MXPA05009178A (cg-RX-API-DMAC7.html)
NZ (1) NZ542071A (cg-RX-API-DMAC7.html)
PL (1) PL209998B1 (cg-RX-API-DMAC7.html)
RU (1) RU2364625C2 (cg-RX-API-DMAC7.html)
TW (1) TW200506061A (cg-RX-API-DMAC7.html)
WO (1) WO2004076651A2 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
WO2005037995A2 (en) * 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
AU2006249640C1 (en) 2005-04-08 2016-10-13 Coimmune, Inc. Dendritic cell compositions and methods
EP1957634A4 (en) * 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc COMPOSITIONS AND METHODS OF INDUCING THE ACTIVATION OF UNREFERENCE MONOCYTIC DENDRITE CELLS
EP1806395A1 (en) * 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation of dendritic cells
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
KR100896747B1 (ko) 2007-05-30 2009-05-11 동아대학교 산학협력단 후코이단 또는 그 유사체를 함유하는 수지상 세포의 성숙화유도용 조성물
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
JP2010063404A (ja) * 2008-09-10 2010-03-25 Olympus Corp 幹細胞の分離方法
FR2940451B1 (fr) * 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
NZ597724A (en) * 2009-07-24 2013-10-25 Rhode Island Hospital Dendritic cell vaccines for asparaginyl-beta-hydroxylase expressing tumors
AU2010307075B2 (en) * 2009-10-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
JP2013522309A (ja) * 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 活性化した成熟樹状細胞を調製し保存するシステムおよび方法
RU2458985C1 (ru) * 2011-03-18 2012-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической иммунологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКИ" СО РАМН) Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью
SG11201404570WA (en) * 2012-02-10 2014-11-27 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
CN104098652B (zh) * 2014-07-23 2016-11-09 国家纳米科学中心 一种抑制肿瘤转移的多肽和多肽复合物、其制备方法及其应用
DK3173420T3 (da) * 2014-07-23 2021-10-18 Nat Ct Nanoscience & Technology China Polypeptid og polypeptidkompleks til undertrykkelse af tumormetastase og behandling af leukæmi samt fremgangsmåde til fremstilling deraf og anvendelse deraf
MX2018000056A (es) * 2015-06-30 2018-05-28 Northwest Biotherapeutics Inc Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
CA2998614A1 (en) 2015-09-15 2017-03-23 Northwest Biotherapeutics, Inc. Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
CN105483084A (zh) * 2016-01-04 2016-04-13 英普乐孚生物技术(上海)有限公司 肿瘤抗原靶向性dc细胞的制备方法
WO2019246111A1 (en) 2018-06-19 2019-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand
KR102159766B1 (ko) * 2018-11-12 2020-09-24 조선대학교산학협력단 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법
CA3135852A1 (en) * 2019-04-03 2020-10-08 Akron Biotechnology, Llc Cryopreservation and cell culture media
EP3984597A4 (en) * 2019-07-12 2023-07-12 Kyushu University, National University Corporation DEVELOPMENT OF A THERAPY TO IMPROVE MYOCARDIAL CONTRACTION AND A METHOD OF INHIBITION OF CARDIOMYOCYTE DEATH
EP4061423A4 (en) * 2019-11-18 2023-12-06 Children's Medical Center Corporation HYPERACTIVE DENDRITIC CELLS FOR PERMANENT ANTITUMOR EFFECT ON ADOPTIONAL CELL TRANSFER BASIS
KR102904431B1 (ko) * 2021-05-07 2025-12-26 (주)나노팬텍 수지상 세포의 배양 방법
JP7652461B2 (ja) * 2021-05-07 2025-03-27 ナノファエンテック カンパニー リミテッド 樹状細胞の培養方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法
US12584107B2 (en) * 2022-01-20 2026-03-24 3T Biosciences, Inc. T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells
US20230287448A1 (en) * 2022-01-20 2023-09-14 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
CN118389430A (zh) * 2024-04-12 2024-07-26 广东壹加再生医学研究院有限公司 一种高抗肿瘤特异性dc-cik细胞的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0205387B1 (en) * 1985-06-11 1992-02-26 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Human monocytes cultured in suspension in serum-free medium
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
WO2003010292A2 (en) * 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
BRPI0212545B8 (pt) * 2001-09-06 2021-05-25 Northwest Biotherapeutics Inc método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
JP4567446B2 (ja) 2002-06-19 2010-10-20 ノースウエスト バイオセラピューティクス,インコーポレイティド 白血球富化のための平行流濾過デバイスおよび方法
JP2006517108A (ja) * 2003-02-10 2006-07-20 ノースウエスト バイオセラピューティクス,インコーポレイティド 培養されたcd14+抗原提示細胞

Also Published As

Publication number Publication date
WO2004076651A2 (en) 2004-09-10
NZ542071A (en) 2007-11-30
US9102917B2 (en) 2015-08-11
EP1604016A4 (en) 2006-03-08
ES2321939T3 (es) 2009-06-15
CN1784488A (zh) 2006-06-07
RU2005129561A (ru) 2006-03-10
IL170512A (en) 2013-12-31
JP4762887B2 (ja) 2011-08-31
WO2004076651A3 (en) 2005-03-10
US8389278B2 (en) 2013-03-05
EP1604016B1 (en) 2009-01-14
TW200506061A (en) 2005-02-16
KR101201875B1 (ko) 2012-11-15
US20130273654A1 (en) 2013-10-17
US10731130B2 (en) 2020-08-04
KR20050107471A (ko) 2005-11-11
BRPI0407900A (pt) 2006-03-21
EP1604016A2 (en) 2005-12-14
PL209998B1 (pl) 2011-11-30
CY1109099T1 (el) 2014-07-02
AU2010201319B2 (en) 2012-09-06
ATE420946T1 (de) 2009-01-15
CA2517295C (en) 2016-01-12
JP2006519021A (ja) 2006-08-24
MXPA05009178A (es) 2006-03-08
US20160024472A1 (en) 2016-01-28
US11827903B2 (en) 2023-11-28
DE602004019057D1 (de) 2009-03-05
AU2004214896A1 (en) 2004-09-10
RU2364625C2 (ru) 2009-08-20
HK1086597A1 (en) 2006-09-22
KR20110106474A (ko) 2011-09-28
US20210102169A1 (en) 2021-04-08
CN1784488B (zh) 2010-07-28
AU2010201319A1 (en) 2010-04-29
CA2517295A1 (en) 2004-09-10
PL378291A1 (pl) 2006-03-20
US20040203143A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
PL378291A1 (pl) Wytwarzanie komórek dendrytycznych z monocytarnych prekursorów komórek dendrytycznych z zastosowaniem GM-CSF w nieobecności dodatkowych cytokin
Khosravi et al. Induction of CD4+ CD25+ FOXP3+ regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation
Đokić et al. Mesenchymal stem cells from periapical lesions modulate differentiation and functional properties of monocyte‐derived dendritic cells
WO2006065495A3 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
Jongmans et al. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails
EP2722387A3 (en) Definitive endoderm
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
BRPI0212545B8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
NZ598657A (en) Anti-il-6 antibodies, compositions, methods and uses
RU2008122550A (ru) Композиции и способы индуцирования активации незрелых моноцитарных дендритных клеток
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
PH12020551151A1 (en) Method of producing natural killer cells and composition for treating cancer
NZ600075A (en) Means and methods for influencing the stability of antibody producing cells
WO2003083089A3 (en) Tolerogenic antigen-presenting cells
CN116004533A (zh) iNKT细胞的激活扩增方法及其培养基组合
WO2012118349A3 (ko) 제대혈 cd14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법
EP1572989B1 (fr) Lignee de cellules dendritiques gen2.2
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
EP2377922A3 (en) PDX1 expressing endoderm
AU2001259744A1 (en) Compositions and methods for producing antigen-presenting cells
O'Connell et al. Type‐1 polarized nature of mouse liver CD8α–and CD8α+ dendritic cells: tissue‐dependent differences offset CD8α‐related dendritic cell heterogeneity
EP2484759A3 (en) Methods of refolding mammalian glycosyltransferases
WO2003100010A3 (en) Cytokine-free growth and maintenance of progenitor cells
CA2442300A1 (en) Cd8.alpha. + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation
WO2005023982A3 (en) Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients